In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves

The Journal of Antimicrobial Chemotherapy
Yan LiHongjian Li

Abstract

To investigate the in vitro interaction between three azoles (fluconazole, itraconazole and voriconazole) and cyclosporin A against five azole-susceptible (azole-S) and five azole-resistant (azole-R) clinical Candida albicans isolates. By using a chequerboard technique and time-kill curves, synergistic, indifferent or antagonistic effects when drugs were used in combination were assessed. In the chequerboard assay, the antifungal activity of drug combinations was determined by the microdilution method based on the CLSI M27-A2 guidelines. The effects of the interactions were assessed by two non-parametric approaches (fractional inhibitory concentration index model and deltaE model). In the time-kill assay, a colony counting method was employed against one azole-S strain and one azole-R strain at 0, 6, 12, 24 and 48 h of incubation at 35 degrees C. Good concordance was found between the chequerboard method and time-kill curves. Indifference or synergism was observed for azole-S isolates in interactions of azoles and cyclosporin A, while strong synergism was observed for azole-R isolates in all drug combinations. Cyclosporin A showed potent synergism when combined with the three azoles, especially against azole-R C. albicans strai...Continue Reading

Citations

May 20, 2009·Antimicrobial Agents and Chemotherapy·Eric DannaouiOlivier Lortholary
May 8, 2009·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Hong ZhangWanqing Liao
Jan 30, 2014·Expert Opinion on Drug Delivery·Chau-Minh PhanLyndon Jones
May 27, 2014·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Hui LiShujuan Sun
Sep 17, 2014·Journal of Biomaterials Science. Polymer Edition·Chau-Minh PhanLyndon Jones
Aug 4, 2016·Future Medicinal Chemistry·Jose A Reales-CalderónJosé L Martínez
Oct 25, 2017·Antimicrobial Agents and Chemotherapy·April C JoiceKarl A Werbovetz
Oct 12, 2018·Journal of Applied Microbiology·M ZhangS Sun
Apr 2, 2019·The Journal of Antimicrobial Chemotherapy·Patrick SchwarzEric Dannaoui
Sep 17, 2013·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Sema Aşkin KeçeliPenbe Cağatay
Jul 15, 2020·Antimicrobial Agents and Chemotherapy·Gina Wall, Jose L Lopez-Ribot
Jan 30, 2021·Journal of Global Antimicrobial Resistance·Haisheng ChenWenna Shi
Feb 10, 2021·Journal of Fungi·Anne-Laure BidaudEric Dannaoui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.